Adaptive Historical Income Statement
| ADPT Stock | USD 6.46 0.00 0.00% |
Historical analysis of Adaptive Biotechnologies income statement accounts such as Discontinued Operations of 0.0, Depreciation And Amortization of 13.1 M or Interest Expense of 14.5 M can show how well Adaptive Biotechnologies Corp performed in making a profits. Evaluating Adaptive Biotechnologies income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Adaptive Biotechnologies's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Adaptive Biotechnologies latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Adaptive Biotechnologies is a good buy for the upcoming year.
Adaptive |
About Adaptive Income Statement Analysis
Adaptive Biotechnologies Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Adaptive Biotechnologies shareholders. The income statement also shows Adaptive investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Adaptive Biotechnologies Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts Adaptive Biotechnologies generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Most accounts from Adaptive Biotechnologies' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Adaptive Biotechnologies current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adaptive Biotechnologies Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. At this time, Adaptive Biotechnologies' Interest Income is comparatively stable compared to the past year. Interest Expense is likely to gain to about 14.5 M in 2024, whereas Selling General Administrative is likely to drop slightly above 57.1 M in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 105.0M | 127.4M | 94.7M | 82.4M | Total Revenue | 154.3M | 185.3M | 170.3M | 123.7M |
Adaptive Biotechnologies income statement Correlations
Click cells to compare fundamentals
Adaptive Biotechnologies Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Adaptive Biotechnologies income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Net Interest Income | 9.8M | 6.6M | 1.7M | (182K) | (853K) | (810.4K) | |
| Interest Income | 9.8M | 6.6M | 1.7M | 4.1M | 13.5M | 14.2M | |
| Depreciation And Amortization | 171.9K | 11.7M | 21.0M | 28.1M | 22.2M | 13.1M | |
| Selling General Administrative | 30.3M | 49.5M | 74.5M | 88.5M | 83.9M | 57.1M | |
| Selling And Marketing Expenses | 38.5M | 61.4M | 95.5M | 95.6M | 88.6M | 66.1M | |
| Total Revenue | 85.1M | 98.4M | 154.3M | 185.3M | 170.3M | 123.7M | |
| Gross Profit | 62.8M | 75.9M | 105.0M | 127.4M | 94.7M | 82.4M | |
| Other Operating Expenses | 163.5M | 251.2M | 363.3M | 385.5M | 397.3M | 274.7M | |
| Operating Income | (78.4M) | (152.8M) | (209.0M) | (200.2M) | (227.0M) | (215.7M) | |
| Net Income From Continuing Ops | (68.6M) | (146.2M) | (207.3M) | (200.4M) | (196.0M) | (205.8M) | |
| Ebit | (76.9M) | (156.1M) | (214.3M) | (196.1M) | (211.5M) | (222.1M) | |
| Research Development | 70.7M | 116.1M | 142.3M | 141.8M | 122.1M | 104.4M | |
| Ebitda | (76.7M) | (144.3M) | (193.3M) | (168.0M) | (189.3M) | (198.7M) | |
| Cost Of Revenue | 22.3M | 22.5M | 49.3M | 57.9M | 75.6M | 41.3M | |
| Total Operating Expenses | 141.2M | 228.7M | 314.0M | 327.6M | 321.8M | 233.4M | |
| Reconciled Depreciation | 7.8M | 8.5M | 14.0M | 20.9M | 22.1M | 13.4M | |
| Income Before Tax | (68.6M) | (146.2M) | (207.3M) | (200.4M) | (225.3M) | (214.0M) | |
| Total Other Income Expense Net | 9.8M | 6.6M | 1.7M | (182K) | 1.7M | 2.5M | |
| Net Income Applicable To Common Shares | (69.6M) | (146.2M) | (207.3M) | (200.2M) | (180.2M) | (189.2M) | |
| Net Income | (58.8M) | (139.6M) | (205.6M) | (142.5M) | (225.3M) | (214.0M) | |
| Income Tax Expense | (9.8M) | (6.6M) | (1.7M) | (57.9M) | (54K) | (56.7K) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Adaptive Stock Analysis
When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.